Search results

Order by most recent / most popular / relevance

Results: 1-10 of 18

Dispelling the Myriad gene patent harmonization myth

Foley & Lardner LLP
-
Australia, Canada, European Union, France, Germany, Japan, USA
-
April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Patents and Canadian competition laws

Gowling Lafleur Henderson LLP
-
Canada, USA
-
April 22 2013

In Canada, the Competition Act largely defers to the Patent Act. For example, the Act's abuse of dominance provision (s. 79 Canada's

Northern exposure?

Gowling Lafleur Henderson LLP
-
Canada, USA
-
April 4 2013

Davit Akman and John Norman suggest that a recently commenced investigation into alleged "product switching" and statements by the Interim

Apple’s win could put smartphone competitors in a pinch

Norton Rose Canada LLP
-
Canada, USA
-
August 30 2012

A jury ruling in Apple’s favour over Samsung in the United States District Court could have a chilling effect on rivals, and leave them scrambling for alternatives to common touch-screen gestures used in consumer electronic devices

"Anti-suit" injunction in respect of action in Illinois court denied

Borden Ladner Gervais LLP
-
Canada, USA
-
August 29 2012

Agemian brought the within application in the Ontario Superior Court of Justice, seeking an injunction against the Respondents to prevent them from pursuing a patent infringement action in the United States, Northern District of Illinois-Eastern Division (the "Illinois Court"

Life sciences & law current issues 201213

Gowling Lafleur Henderson LLP
-
Canada, European Union, USA
-
June 18 2012

Each stage of the life cycle of a company or a product presents challenges that demand the expertise and resources of a strong legal partner

Common sense and obviousness: supporting evidence is required

Bereskin & Parr LLP
-
Canada, USA
-
June 12 2012

Whether enforcing a patent or prosecuting a patent application, obviousness is often the key issue

The U.S. Prometheus decision and claims to methods of optimizing dosing regimens: Mayo Collaborative Services v. Prometheus Laboratories, Inc., U.S., No. 10-1150

Gowling Lafleur Henderson LLP
-
Canada, USA
-
April 11 2012

In a decision last month, the U.S. Supreme Court in a 9-0 ruling has held that the method claims of two patents directed to optimizing the dose of a specific drug for treating an autoimmune disease are not patentable because they merely recite laws of nature

Determining patentable subject matter in the United States and Canada

Bereskin & Parr LLP
-
Canada, USA
-
April 10 2012

As reported in our March 21, 2012, Spring Alert, the United States Supreme Court recently held in Prometheus v. Mayo that certain personalized medicine claims were directed to laws of nature and were thus unpatentable despite containing both an administering step and a determining step

Confirmation of the patentability of DNAgene sequences in the United States

Borden Ladner Gervais LLP
-
Canada, USA
-
December 21 2011

Canadian courts showed promising support for DNAgene patents by ruling in favour of Monsanto in its often-cited patent infringement case

next >

Search results

Dispelling the Myriad gene patent harmonization myth

Patents and Canadian competition laws

Northern exposure?

Apple’s win could put smartphone competitors in a pinch

"Anti-suit" injunction in respect of action in Illinois court denied

Life sciences & law current issues 201213

Common sense and obviousness: supporting evidence is required

The U.S. Prometheus decision and claims to methods of optimizing dosing regimens: Mayo Collaborative Services v. Prometheus Laboratories, Inc., U.S., No. 10-1150

Determining patentable subject matter in the United States and Canada

Confirmation of the patentability of DNAgene sequences in the United States

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea